Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000–2020

References

• Baselt RC. Disposition of toxic drugs and chemicals in man. 12th ed. CA: Biomedical Publications; 2020.
   Google Scholar
• Brunton L, Channer B, Knollman B. Goodman & Gilman’s the pharmaceutical basis of therapeutics. New York: McGraw Hill; 2011.
   Google Scholar
• Karch SB. Karch's pathology of drug abuse. 5th ed. Boca Raton: CRC Press; 2015.
   Google Scholar
• Leikin JB, Paloucek FP. Poisoning and toxicology handbook. 4th ed. Boca Raton: CRC Press; 2015.
   Google Scholar
• Cairns R, Schaffer AL, Ryan N, et al. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction. 2019;114(6):1026–1034.
   PubMed Web of Science ®Google Scholar
• Brett J, Pearson SA, Daniels B, et al. A cross sectional study of psychotropic medicine use in Australia in 2018: a focus on polypharmacy. Br J Clin Pharmacol. 2021;87(3):1369–1377.
   PubMed Web of Science ®Google Scholar
• Chiu T, Brett J, Pearson SA, et al. Patterns of pregabalin initiation and discontinuation after its subsidy in Australia. Br J Clin Pharmacol. 2020;86(9):1882–1887.
   PubMed Web of Science ®Google Scholar
• Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292–414.
   PubMed Web of Science ®Google Scholar
• Kwok H, Khuu W, Fernandes K, et al. Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis. Pain Med. 2017;18(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580–1589.
   PubMed Web of Science ®Google Scholar
• Pauly NJ, Delcher C, Slavova S, et al. Trends in gabapentin prescribing in a commercially insured US adult population, 2009–2016. J Manag Care Spec Pharm. 2020;26:246–252.
   PubMed Web of Science ®Google Scholar
• Schaffer AL, Busingye D, Chidwick K, et al. Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study. BJGP Open. 2021;5:bjgpopen20X101120.
   PubMedGoogle Scholar
• Schjerning O, Rosenzweig M, Pottegård A, et al. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30(1):9–25.
   PubMed Web of Science ®Google Scholar
• Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013;347:f6747.
   PubMedGoogle Scholar
• Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185–1215.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–426.
   PubMed Web of Science ®Google Scholar
• Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69(12):2021–2025.
   PubMed Web of Science ®Google Scholar
• Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry. 2015;172(5):487–488.
   PubMed Web of Science ®Google Scholar
• Tharp AM, Hobron K, Wright T. Gabapentin-related deaths: patterns of abuse and postmortem levels. J Forensic Sci. 2019;64(4):1105–1111.
   PubMed Web of Science ®Google Scholar
• Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24(2):173–177.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826–836.
   PubMed Web of Science ®Google Scholar
• Sutherland R, Dietze PM, Gisev N, et al. Patterns and correlates of prescribed and non-prescribed pregabalin use among a sample of people who inject drugs in Australia. Drug Alcohol Rev. 2020;39(5):568–574.
   PubMed Web of Science ®Google Scholar
• Crossin R, Scott D, Arunogiri S, et al. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. Med J Aust. 2019;210(2):75–79.
   PubMed Web of Science ®Google Scholar
• Daly C, Griffin E, Ashcroft DM, et al. Intentional drug overdose involving pregabalin and gabapentin: findings from the National Self-Harm Registry Ireland, 2007–2015. Clin Drug Investig. 2018;38(4):373–380.
   PubMed Web of Science ®Google Scholar
• Handley SA, Ramsey JD, Flanagan RJ. Substance misuse-related poisoning deaths, England and Wales, 1993–2016. Drug Sci Policy Law. 2018;4:205032451876744.
   Google Scholar
• Molero Y, Larsson H, D’Onofrio BM, et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ Clin Res. 2019;365:12147.
   Google Scholar
• Middleton O. Suicide by gabapentin overdose. J Forensic Sci. 2011;56(5):1373–1375.
   PubMed Web of Science ®Google Scholar
• De Landaluce LO, Carbonell P, Asensio C, et al. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf. 2018;41(12):1325–1331.
   PubMed Web of Science ®Google Scholar
• Cantrell FL, Mena O, Gary RD, et al. An acute gabapentin fatality: a case report with postmortem concentrations. Int J Legal Med. 2015;129(4):771–775.
   PubMed Web of Science ®Google Scholar
• Eastwood JA, Davison E. Pregabalin concentrations in post-mortem blood—a two year study. Forensic Sci Int. 2016;266:197–201.
   PubMed Web of Science ®Google Scholar
• Elliott SP, Burke T, Smith C. Determining the toxicological significance of pregabalin in fatalities. J Forensic Sci. 2017;62(1):169–173.
   PubMed Web of Science ®Google Scholar
• Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study. PLoS Med. 2017;14(10):e1002396.
   PubMed Web of Science ®Google Scholar
• Häkkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.
   PubMed Web of Science ®Google Scholar
• Hamm CE, Gary RD, McIntyre IM. Gabapentin concentrations and postmortem distribution. Forensic Sci Int. 2016;262:201–203.
   PubMed Web of Science ®Google Scholar
• Lottner-Nau S, Övgüer B, Paul LD, et al. Abuse of pregabalin – results of the postmortem toxicology from 2010 to 2012. Toxichem Krimtech. 2013;80:339–342.
   Google Scholar
• Nahar L, Smith A, Patel R, et al. Validated method for the screening and quantification of baclofen, gabapentin and pregabalin in human post-mortem whole blood using protein precipitation and liquid chromatography–tandem mass spectrometry. J Anal Toxicol. 2017;41(5):441–450.
   PubMed Web of Science ®Google Scholar
• Priez-Barallon C, Carlier J, Boyer B, et al. Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MS in postmortem human samples: eighteen case reports. J Anal Toxicol. 2014;38(3):143–148.
   PubMed Web of Science ®Google Scholar
• Ramoo B, Tarau MC, Dudley M, et al. Gabapentin related fatality: a case study. Tox Talk. 2014;38:19–21.
   Google Scholar
• Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018;186:80–85.
   PubMed Web of Science ®Google Scholar
• Kitzman DW, Scholz D,G, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity): a quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc. 1988;63(2):137–146.
   PubMed Web of Science ®Google Scholar
• Scholz D,G, Kitzman DW, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part I (growth): a quantitative anatomic study of 200 specimens from subjects from birth to 19 years old. Mayo Clin Proc. 1988;63(2):126–136.
   PubMed Web of Science ®Google Scholar
• IBM Inc. SPSS for windows, 22.0. Chicago (IL): SPSS Inc.; 2013.
   Google Scholar
• Chrzanowska A, Man N, Sutherland R, et al. Trends in drug-induced deaths in Australia, 1997–2019. Drug trends bulletin series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2021.
   Google Scholar
• Campbell G, Bruno R, Darke S, et al. Prevalence and correlates of suicidal thoughts and suicide attempts in people prescribed pharmaceutical opioids for chronic pain. Clin J Pain. 2016;32(4):292–301.
   PubMed Web of Science ®Google Scholar
• Campbell G, Darke S, Lappin J, et al. Prevalence and characteristics associated with chronic non-cancer pain in suicide decedents: a national study. Suicide Life Threat Behav. 2020;50(4):778–791.
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health. Opioid analgesics. Pharmaceutical benefits scheme drug utilisation sub-committee report. Canberra: Australian Government Department of Health; 2020.
   Google Scholar
• Australian Institute of Health and Welfare. Suicide and intentional self-harm. Canberra: Australian Institute of Health and Welfare; 2020.
   Google Scholar